

PRODUCT

DRUG DISC.

PRECLINICAL

PHASE I

PHASE II

PARTNER

VALIDATION PROGRAMS


mGluR4 PAM (Foliglurax) / Parkinson#




A2A/A1 antagonist (CVXL0069) / Parkinson




SEMA3A (SGL10060) / Oncology



Adenosine R Antagonists / Immuno-oncology



mGluR3 PAM / Parkinson#



Multi-target TM Peptides / CNS-Oncology



INTERNAL PROGRAMS

mGluR3 NAM / Oncology



mGluR4 PAM / Parkinson-Immune Diseases



NPFF / Pain



Undisclosed GPCR/ Immuno-Oncology



OPTION PROGRAMS

Multiple programs



Project supported by

